4.5 Review

Secondary Progressive Multiple Sclerosis: Definition and Measurement

期刊

CNS DRUGS
卷 30, 期 6, 页码 517-526

出版社

ADIS INT LTD
DOI: 10.1007/s40263-016-0340-9

关键词

-

资金

  1. UK National Institute for Health Research (NIHR) University College London Hospitals/University College London Biomedical Research Centres Funding scheme

向作者/读者索取更多资源

Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms underlying neurodegeneration in multiple sclerosis (MS) may explain why, to date, there is no definitive imaging or laboratory test that is able to inform us when the disease is clearly entering into a progressive phase and why the vast majority of clinical trials testing immunosuppressant and immunomodulating drugs in SPMS patients has so far yielded disappointing or mixed results. Here we discuss the definition(s) of SPMS and how it may vary, outcome measurements (current and emerging) and modern trial design.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据